Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10041784HBVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS10041785HBVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30009838HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30011116HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30016681HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30016680HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30009839HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30085762HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072171HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072172HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TCGA Plot Options
Drug Information
GeneABL1
DrugBank IDDB12267
Drug NameBrigatinib
Target IDBE0000014
UniProt IDP00519
Regulation Typeinhibitor
PubMed IDs28597393; 23239810
CitationsMarkham A: Brigatinib: First Global Approval. Drugs. 2017 Jul;77(10):1131-1135. doi: 10.1007/s40265-017-0776-3.@@Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C: Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13.
GroupsApproved; Investigational
Direct ClassificationPhenylpiperidines
SMILESCOC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1
Pathways
PharmGKBPA166163482
ChEMBLCHEMBL3545311